BTK and chronic neutrophilic leukemia: Although a Phase II clinical trial (NCT02415608) of ibrutinib in systemic mastocytosis was recently terminated due to slow accrual, these preclinical findings suggest a potential of ibrutinib and other BTK inhibitors as new therapeutic agents for CNL and mast cell neoplasms.